From Nerve Conduction to Symptom Relief: Palm Tocotrienols in Diabetic Peripheral Neuropathy—Reconciling Mechanistic Promise with Clinical Discordance: A Critical Review

Abstract

Diabetic peripheral neuropathy (DPN) remains one of the most prevalent and disabling complications of diabetes and is characterized by progressive sensory dysfunction, neuropathic pain, loss of protective sensation, impaired mobility, foot ulceration, and increased amputation risk. Current pharmacological treatment is primarily symptom-oriented, whereas therapies capable of reliably preventing or reversing established peripheral nerve injury remain limited.

Palm-derived tocotrienols have attracted clinical interest because their antioxidant, anti-inflammatory, metabolic, and neuroprotective activities intersect with several mechanisms implicated in DPN.

However, clinical evidence is discordant. Tocotrienol-rich vitamin E has produced improvements in selected nerve-conduction parameters and neurotrophic biomarkers, whereas larger clinical studies have not demonstrated consistent improvements in overall neuropathic symptoms or neurological impairment.